Update on therapy of influenza and rhinovirus infections

Advances in Experimental Medicine and Biology

Volumn 394, Issue , 1996, Pages 175-187

  Arruda, Eurico ^b   Hayden, Frederick G ^b  

^a UNIVERSITY OF VIRGINIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 (5 TETRADECYLOXY 2 FURANYL)ETHANONE; 3 METHOXY 6 [4 (3 METHYLPHENYL) 1 PIPERAZINYL]PYRIDAZINE; 5 [5 [2,6 DICHLORO 4 (4,5 DIHYDRO 2 OXAZOLYL)PHENOXY]PENTYL] 3 METHYLISOXAZOLE; ALPHA2 INTERFERON; AMANTADINE; AMITIVIR; APROTININ; CHALCONE DERIVATIVE; CHLORPHENIRAMINE MALEATE; CROFELEMER; FLAVONOID; GUANOSINE DERIVATIVE; INTERCELLULAR ADHESION MOLECULE 1 ANTIBODY; IPRATROPIUM BROMIDE; KANAMYCIN DERIVATIVE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLEPHRINE; PIRODAVIR; POLYPHENOL DERIVATIVE; RECEPTOR ANTIBODY; RECOMBINANT BETA INTERFERON; RIMANTADINE; SIALIC ACID DERIVATIVE; SIALIDASE; SIALIDASE INHIBITOR; THIADIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VIRUS RECEPTOR; ZANAMIVIR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; CLINICAL TRIAL; COMMON COLD; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOG; DOSE RESPONSE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; HUMAN; INFLUENZA VIRUS A; INFLUENZA VIRUS B; INHALATIONAL DRUG ADMINISTRATION; INTRANASAL DRUG ADMINISTRATION; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RHINOVIRUS; TOPICAL DRUG ADMINISTRATION; VIRUS SHEDDING;

ANIMALIA; CANIS FAMILIARIS; INFLUENZA VIRUS; INFLUENZAVIRUS A; INFLUENZAVIRUS B; RESPIRATORY SYNCYTIAL VIRUS; RHINOVIRUS;

EID: 0029987042     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4757-9209-6_18     Document Type: Conference Paper

References (93)

1. Hayden FG. Use of interferons for prevention and treatment of respiratory viral infections. In: Antiviral Chemotherapy, New Directions for Clinical Application and Research, Mills J and Corey L (eds.), Elsevier, New York, NY, 1986, pp 28-39.
2. Hayden FG. Update on antiviral chemotherapy of respiratory viral infection. In: Antiviral Chemotherapy, New Directions for Clinical Application and Research, Vol 2, Mills J and Corey L (eds.), Elsevier, New York, NY, 1989, pp 117-42.
3. Hayden FG. Update on treatment of respiratory viral infections. In: Antiviral Chemotherapy, New Directions for Clinical Applicalion and Research, Vol 3, Mills J and Corey L (eds.), PTR Prentice-Hall, Englewood Cliffs, NJ, 1993, pp 207-28.
4. Tominack RL, Hayden FG. In: Infectious Disease Clinics of North America, Rimantadine hydrochloride and amantadine hydrochloride use in influenza A virus infections, Moellering RC, ed., W.B. Saunders, Philadelphia, 1987, pp 459-78.
5. Douglas RG, Jr. Drug therapy. Prophylaxis and treatment of influenza. N Engl J Med 1990;322:443-50.
6. Peters NL, Oboler S, Hair C, et al. Treatment of an influenza A outbreak in a teaching nursing home. J Am Geriatr Soc 1989;37:210-18.
7. Degelau J, Somani S, Cooper SL, et al. Occurrence of adverse effects and high amantadine concentrations with influenza prophylaxis in the nursing home. J Am Geriatr Soc 1990;38:428-32.
8. Stange KC, Little DW, Blatnik B. Adverse reactions to amantadine prophylaxis of influenza in a retirement home. J Am Geriatr Soc 1991:33:700-5.
9. Brady MT, Sears SD, Pacini DL, et al. Safety and prophylactic efficacy of low-dose rimantadine in adults during an influenza A epidemic. Antimicrob Agents Chemother 1990;34:1633-36.
10. Hay AJ. The action of adamantanamines against influenza A viruses: inhibition of the M2 ion channel protein. Seminars in Virology 1992;3:21-30.
11. Duff KC, Gilchrist PJ, Saxena AM, et al. Neutron diffraction reveals the site of amantadine blockade in the influenza A M2 ion channel. Virology 1994;202:287-93.
12. Hayden FG, Couch RB. Clinical and epidemiological importance of influenza A viruses resistant to amantadine and rimantadine. Rev Med Virol 1992;2:89-96.
13. Hayden FG. Amantadine and rimantadine resistance in influenza A viruses. Current Opinion in Infectious Diseases 1994;7:674-77.
14. Degelau J, Somani SK, Cooper SL, et al. Amantadine-resistant influenza A in a nursing facility. Arch Intern Med 1992;152:390-92.
15. Palese P, Compans RW. Inhibition of influenza virus replication in tissue culture by 2-deoxy-2,3-dehydro-N-trifluoroacetylneuraminic acid (FANA): mechanism of action. J Gen Virol 1976;33:159-63.
16. Burnet FM, McCrea, Anderson SG, Mucin as a substrate of enzyme action by viruses of the mumps influenza group. Nature (London) 1947;160:404-5.
17. Shengqiang LI, Schulman J, Itamura S, et al. Glycosylation of neuraminidase determines the neurovirulence of influenza A/WSN/33 virus. J Virol 1993;67:6667-73.
18. Liu C, Air GM. Selection and characterization of a neuraminidase-minus mutant of influenza virus and its rescue by cloned neurammidase genes. Virology 1993;194:403-7.
19. Colman PM, Varghese JN, Laver WG. Structure of the catalytic and antigenic sites in influenza virus neuraminidase. Nature 1983;303:41-4.
20. Varghese JN, McKimm-Breschkin JL, Caldwell JB, et al. The structure of the complex between influenza virus neuraminidase and sialic acid, the viral receptor. Proteins: Structure, Function, and Genetics 1992;14:327-32.
21. Murphy BR, Kasel JA, Chanock RM. Association of serum anti-neuraminidase antibody with resistance to influenza in man. JAMA 1972;286:1329-32.
22. Monto AS, Kendal AP. Effect of neuraminidase antibody of Hong Kong influenza. Lancet 1973;623-25.
23. Couch RB, Kasel JA, Gerin JL, et al. Induction of partial immunity to influenza by a neuraminidase-specific vaccine. J Infect Dis 1974;129:411-20.
24. Beutner KR, Chow T, Rubi E, et al. Evaluation of a neuraminidase-specific influenza A virus vaccine in children: antibody responses and effects on two successive outbreaks of natural infection. J Infect Dis 1979;140:844-50.
25. Webster RG, Reay PA, Laver WG. Protection against lethal influenza with neuraminidase. Virology 1988;164:230-7.
26. Meindl P, Bodo G, Palese P, et al. Inhibition of neuraminidase activity by derivatives of 2-deoxy-2,3-dehydro-N-acetylneuraminic acid (FANA). Virology 1974;58:457-63.
27. Palese P, Schulman JL. Inhibition of influenza and parainfluenza virus replication in tissue culture by 2-deoxy-2, 3-dehydro-N-trifluoroacetylneuraminic acid (FANA). Virology 1974;59:490-98.
28. von Itzstein M, Wu WY, Kok GB, et al. Rational design of potent sialidase-based inhibitors of influenza virus replication. Nature 1993;363:418-23.
29. Ryan DM, Ticehurst J, MH Dempsey, et al. Inhibition of influenza virus replication in mice by GG167 (4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid) is consistent with extracellular activity of viral neuraminidase (sialidase). Antimicrob Agents Chemother 1994;38:2270-75.
30. Pegg MS, von Itzstein M. Slow-binding inhibition of sialidase from influenza virus. Biochemistry Molecular Biology International 1994;32:851-8.
31. Woods JM, Bethell RC, Coates JAV, et al. 4-guanidino-2,4-dideoxy-2,3-dehydro-N-acetylneuraminic acid is a highly effective inhibitor both of the sialidase (neuraminidase) and of growth of a wide range of influenza A and B viruses in vitro. Antimicrob Agents Chemother 1993;37:1473-79.
32. Hayden FG, Rollins BS, Madren LK. Anti-influenza virus activity of the neuraminidase inhibitor 4-guanidino-Neu5Ac2en in cell culture and in human respiratory epithelium. Antiviral Res 1994;25:123-31.
33. Holzer CT, von Itzstein M, Jin B, et al. Inhibition of sialidases from viral, bacterial and mammalian sources by analogues of 2-deoxy-2,3-didehydro-N-acetylneuraminic acid modified at the C-4 position. Glycoconjugate Journal 1993;10:40-44.
34. Thomas GP, Forsyth M, Penn CR, et al. Inhibition of the growth of influenza viruses in vitro by 4-guanidino-2,4-dideoxy-N-acetylneuraminic acid. Antiviral Res 1994;24:351-56.
35. Efthymiopoulos C, Barrington P, Patel J, et al. Pharmacokinetics of the neuraminidase inhibitor 4-guanidino Neu5Ac2en (GG167) following intravenous, intranasal and inhaled administration in man. Program and Abstracts of 34th ICAAC, pp 265, Ameri Soc Microbiol, Orlando, FL, October 4-7, 1994 [abst. H70].
36. Hayden F, Lobo M, Esinhart J, et al. Efficacy of 4-guanidino Neu5Ac2en in experimental human influenza A virus infection. Program and Abstracts of 34th ICAAC, pp 190, Ameri Soc Microbiol, Orlando, FL, October 4-7, 1994 [abst. H35].
37. Colacino JM, DeLong DC, Nelson JR, et al. Evaluation of the anti-influenza virus activities of 1,3,4-thiadiazol-2-ylcyanamide (LY217896) and its sodium salt. Antimicrob Agents Chemother 1990;34:2156-63.
38. Hayden FG, Tunkel AR, Treanor JJ, et al. Oral LY217896 for prevention of experimental influenza A virus infection and illness in humans. Antimicrob Agents Chemother 1994;38:1178-81.
39. Hayden FG, Rollins BS, Hay AJ. Anti-influenza virus activity of the compound LY253963. Antiviral Res 1990;14:25-38.
40. Colacino JM, Birch GM, Tang JC. Cellular metabolism and anti-influenza activity of 1,3,4-thiadiazol-2-ylcyanamide (LY217896). Antiviral Chemistry Chemotherapy 1993;4:271-80.
41. Tisdale M, Appleyard G, Tuttle JV, et al. Inhibition of influenza A and B viruses by 2′-deoxy-2′-fluororibosides. Antiviral Chemistry Chemotherapy 1993;4:281-7.
42. Rollins BS, Elkhatieb AHA, Hayden FG. Comparative anti-influenza virus activity of 2′-deoxy-2′-fluororibosides in vitro. Antiviral Res 1993;21:357-68.
43. Jakeman KJ, Tisdale M, Russell S. Efficacy of 2′-deoxy-2′-fluororibosides against influenza A and B viruses in ferrets. Antimicrob Agents Chemother 1994;38:1864-67.
44. Nagai T, Miyaichi Y, Tomimori T, et al. In vivo anti-influenza virus activity of plant flavonoids possessing inhibitory activity for influenza virus sialidase. Antiviral Res 1992;19:207-17.
45. Zhirnov OP. High protection of animals lethally infected with influenza virus by aprotinin-rimantadine combination. J Med Virol 1987;21:161-67.
46. Ovcharenko AV, Zhirnov OP. Aprotinin aerosol treatment of influenza and paramyxovirus bronchopneumonia of mice. Antiviral Res 1994;23:107-18.
47. Gilbert BE, Wyde PR, Wilson SZ, et al. SP-303 small-particle aerosol treatment of influenza A virus infection in mice and respiratory syncytial virus infection in cotton rats. Antiviral Res 1993;21:37-45.
48. Sidwell RW, Huffman JH, Moscon BJ, et al. Influenza virus-inhibitor effects of intraperitoneally and aerosol-administered SP-303, a plant flavonoid. Chemotherapy 1994;40:42-50.
49. Yamada Y, Shimokata K, Yamada Y, et al. Inhibition of influenza A virus replication by a kanamycin derivative. Antiviral Res 1991;15:171-82.
50. Sperber SJ, Hayden FG. Perspectives in the use of antiviral agents for prevention and treatment of respiratory virus infections. Clinical Use of Antiviral Drugs. (E De Clercq, ed.) 1988, Martinus Nijhoff Publishing, Boston, pp 317-40.
51. Sperber SJ, Hayden FG. Chemotherapy of rhinovirus colds. Antimicrob Agents Chemother 1988;32:409-419.
52. Arruda E, Hayden FG. Clinical studies of antiviral agents for picornaviral infections. Antiviral Chemotherapy. (DJ Jeffries and E DeClercq, ed.) 1995, John Wiley and Sons, New York, NY (in press).
53. Al-Nakib W, Higgins PG, Barrow GI, et al. Suppression of colds in human volunteers challenged with rhinovirus by a new synthetic drug (R61837). Antimicrob Agents Chemother 1989;33:522-25.
54. Barrow GI, Higgins PG, Tyrrell DAJ, et al. An appraisal of the efficacy of the antiviral R 61837 in rhinovirus infections in human volunteers. Antiviral Chem Chemother 1990;1:279-83.
55. Hayden FG, Andries K, Janssen PAJ. Safety and efficacy of intranasal pirodavir (R77975) in experimental rhinovirus infection. Antimicrob Agents Chemother 1992;36:727-732.
56. Sperber SJ, Doyle WJ, McBride TP, et al. Otologic effects of interferon of interferon beta serine in experimental rhinovirus colds. Arch Otolaryngol Head Neck Surg 1992; 118:933-936.
57. Tyrrell D, Barrow I, Arthur J. Local hyperthermia benefits natural and experimental common colds. BMJ 1989;298:1280-83.
58. Hendley JO, Abbott RD, Beasley PP, et al. Effect of inhalation of hot humidified air on experimental rhinovirus infection. JAMA 1994;271:1112-1113.
59. Hayden FG, Hipskind GJ, Janssens M, Janssen PAJ, Andries K. Intranasal pirodavir (R77.975) treatment of rhinovirus colds. Antimicrob Agents Chemother 1995;39:290-294.
60. Ophir D, Elad Y. Effects of steam inhalation on nasal patency and nasal symptoms in patients with the common cold. Am J Otolaryngol 1987;3:149-153.
61. MacKinin ML, Mathew S, Medendorp SV. Effects of inhaling heated vapor on symptoms of the common cold. JAMA 1990;264:989-91.
62. Forstall GJ, Macknin ML, Yen-Lieberman BR, et al. Effect of inhaling heated vapor on symptoms of the common cold. JAMA 1994;271:1109-1111.
63. Andries K, Dewindt B, Snoeks J, et al. In vitro activity of pirodavir (R 77975), a substituted phenoxy-pyridazinamine with broad-spectrum antipicornaviral activity. Antimicrob Agents Chemother 1992;36:100-107.
64. Diana GD, Otto MJ, McKinlay MA. Inhibitors of picornavirus uncoating as antiviral agents. Pharmac Ther 1985;29:287-297.
65. Dewindt BK, van Eemeren K, Andries K. Anti-viral capsid-binding compounds can inhibit the adsorption of minor receptor rhinoviruses. Antiviral Res 1994;25:67-72.
66. Pevear DC, Fancher MJ, Fellock PJ, et al. Conformational change in the floor of the human rhinovirus canyon blocks absorption to HeLa cell receptors. J Virol 1989;63:2002-2007.
67. Shepard DA, Heinz BA, Rueckert RR. WIN 52035-2 inhibits both attachment and eclipse of human rhinovirus 14. J Virol 1993;67:2245-2254.
68. Crump CE, Arruda E, Hayden FG. In vitro inhibitory activity of soluble ICAM-1 for the numbered serotypes of human rhinovirus. Antiviral Chemistry Chemotherapy 1993;4:323-327.
69. Andries K, Dewindt B, Snoeks J, et al. Two groups of rhinoviruses revealed by a panel of antiviral compounds present sequence divergence and differential pathogenicity. J Virol 1990;64:1117-1123.
70. Diana GD, Pevear DC, Otto MJ, et al. Inhibitors of viral uncoating. Pharmac Ther 1989;42:289-305.
71. Andries K, Dewindt B, De Brabander M, et al. In vitro activity of R 61837, a new antirhinovirus compound. Arch Virol 1988;101:155-167.
72. Dearden C, Al-Nakib W, Andries K, et al. Drug resistant rhinoviruses from the nose of experimentally treated volunteers. Arch Virol 1989;109:71-81.
73. Heinz BA, Rueckert RR, Shepard DA, et al. Genetic and molecular analyses of spontaneous mutants of human rhinovirus 14 that are resistant to an antiviral compound. J Virology 1989;63:2476-2485.
74. Yasin SR, Al-Nakib W, Tyrrell DAJ. Pathogenicity for humans of human rhinovirus type 2 mutants resistant to or dependent on chalcone Ro 09-0410. Antimicrob Agents Chemother 1990;34:963-966.
75. Ahmad ALM, Dowsett AB and Tyrrell DAJ. Studies of rhinovirus resistant to an antiviral chalcone. Antivira Res 1987;8:27-39.
76. Woods MG, Diana GD, Rogge MC, et al. In vitro and in vivo activities of WIN 54954, a new broad-spectrum antipicornavirus drug. Antimicrob Agents Chemother 1989;33:2069-2074.
77. Turner RB, Dutko FJ, Goldstein NH, et al. Efficacy of oral WIN 54954 for the prophylaxis of experimental rhinovirus infection. Antimicrob Agents Chemother 1993;37:297-300.
78. Gwallney JM, Jr. Combined antiviral and antimediator treatment of rhinovirus colds. J Infect Dis 1992;166:776-782.
79. Greve JM, Davis G, Meyer AM, et al. The major human rhinovirus receptor is ICAM-1. Cell 1989;56:839-47.
80. Staunton DE, Merluzzi VJ, Rothlem R, et al. A cell adhesion molecule, ICAM-1, is the major surface receptor for rhino-viruses. Cell 1989;56:849-53.
81. Tomassini JE, Graham, D DeWitt CM, et al. cDNA cloning reveals that the major group rhinovirus receptor in HeLa cells is intercellular adhesion molecule-1. Proc Natl Acad Sci 1989;86:4907-4911.
82. Olson NH, Kolatkar PR, Oliveira, MA, et al. Structure of human rhinovirus complexed with its receptor molecule. Proc Natl Acad Sci 1993;90;507-511.
83. Hofer F, Gruenberger M, Kowalski H, et al. Members of the low density lipoprotein receptor family mediate cell entry of a minor-group common cold virus. Proc Natl Acad Sci 1994; 91:1839-1842.
84. Colonno RJ, Callahan PL, Long WJ. Isolation of a monoclonal antibody that blocks attachment of the major group of human rhinoviruses. J Virol 1986;57:7-12.
85. Sperber SJ. Hayden FG. Protective effect of rhinovirus receptor blocking antibody in human fibroblast cells. Antiviral Res 1989;12:231-38.
86. Colonno RJ, Tomassini JE, Callahan PL. Isolation and characterization of a monoclonal antibody which blocks attachment of human rhinoviruses. In Positive Strand RNA Viruses Proceedings of a UCLA Symposium (MA Brinton and R L Rueckert, ed.) Alam Liss. New York, NY 1987, pp 93-102.
87. Hayden FG, Gwallney, JM, Jr., Colonno RJ. Modification of experimental rhinovirus colds by receptor blockade. Antiviral Res 1988;9:233-247.
88. Marlin SD, Staunton DE, Springer TA, et al. A soluble form intercellular adhesion molecule-1 inhibits rhinovirus infection. Nature 1990;334:70-72.
89. Greve JM, Forte CP, Marlor CW, et al. Mechanisms of receptor-mediated rhinovirus neutralization defined by two forms of ICAM-1. J Virol 1991;65:6015-6023.
90. Arruda E, Crump C, Marlin SD, et al. In vitro studies of the anti-rhinovirus activity of soluble ICAM-1. Antimicrob Agents Chemother 1992;36:1186-1191.
91. Martin S, Casasnovas JM, Staunton DE, et al. Efficient netrualization and disruption of rhinovirus by chimeric ICAM-1/immunoglobulin molecules. J Virol 1993;67:3561-68.
92. Crump CE, Arruda E, Hayden FG. Comparative antirhinoviral activities of soluble intercellular adhesion molecule-1 (sICAM-1) and chimeric ICAM-1/immunoglobulin A molecule. Antimicrob Agents Chemother 1994;38:1425-27.
93. Arruda E, Crump CE, Hayden FG. In vitro selection of human rhinovirus relatively resistant to soluble intercellular adhesion molecule-1. Antimicrob Agents Chemother 1994;38:66-70.